Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease.

Kleiner DE, Brunt EM, Wilson LA, Behling C, Guy C, Contos M, Cummings O, Yeh M, Gill R, Chalasani N, Neuschwander-Tetri BA, Diehl AM, Dasarathy S, Terrault N, Kowdley K, Loomba R, Belt P, Tonascia J, Lavine JE, Sanyal AJ, Nonalcoholic Steatohepatitis Clinical Research Network. · 2019

Read Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. by Kleiner DE, Brunt EM, Wilson LA, Behling C, Guy C, Contos M, Cummings O, Yeh M, Gill R, Chalasani N, Neuschwander-Tetri BA, Diehl AM, Dasarathy S, Terrault N, Kowdley K, Loomba R, Belt P, Tonascia J, Lavine JE, Sanyal AJ, Nonalcoholic Steatohepatitis Clinical Research Network. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6784786.txt.

Introduction

Kleiner and co-authors studied what drives fibrosis progression in fatty liver disease. Nonalcoholic fatty liver disease is a leading cause of liver illness. Its aggressive form, steatohepatitis, scars the liver toward cirrhosis. The team followed 446 patients who were not on specific treatments. They asked which factors predicted scarring, and which predicted healing.

A high baseline disease activity score predicted worsening fibrosis. Changes in the score moved together with changes in scarring. Weight gain raised the risk of progression. So did a high or rising level of the liver enzyme AST. Of 86 patients with simple fatty liver, 41.9% progressed toward steatohepatitis. The results support using activity scores as trial endpoints.

Catalog record

CREATORKleiner DE, Brunt EM, Wilson LA, Behling C, Guy C, Contos M, Cummings O, Yeh M, Gill R, Chalasani N, Neuschwander-Tetri BA, Diehl AM, Dasarathy S, Terrault N, Kowdley K, Loomba R, Belt P, Tonascia J, Lavine JE, Sanyal AJ, Nonalcoholic Steatohepatitis Clinical Research Network.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE37 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6784786

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease By David E. Kleiner, Elizabeth M. Brunt, Laura A. Wilson, Cynthia Behling, Cynthia Guy, Melissa Contos, Oscar Cummings, Matthew Yeh, Ryan Gill, Naga Chalasani, Brent A. Neuschwander-Tetri, Anna Mae Diehl Published in: JAMA Network Open DOI: 10.1001/jamanetworkopen.2019.12565 ABSTRACT Key Points Question In patients with nonalcoholic fatty liver disease who are not undergoing specific therapeutic interventions, what factors are associated with progression and regression of hepatic fibrosis? Findings In this cohort study of 446 patients, high baseline nonalcoholic fatty liver disease activity score and changes in the score were associated with concordant changes in fibrosis. Weight gain, high baseline aspartate aminotransferase level, and increases in the aspartate aminotransferase level were associated with fibrosis progression. Meaning These data may support the use of therapeutics targeting disease activity in nonalcoholic steatohepatitis and the use of short-term changes in the nonalcoholic fatty liver disease activity score as an end point in such clinical trials; in clinical practice, weight gain and an increasing aspartate aminotransferase level should increase suspicion of increasing fibrosis. INTRODUCTION Nonalcoholic fatty liver disease (NAFLD) is a leading cause of liver-related morbidity and mortality. Nonalcoholic steatohepatitis (NASH) is an aggressive form of NAFLD and is more likely to progress to cirrhosis compared with nonalcoholic fatty liver (NAFL).1 The growing contribution of NAFLD to the liver-related population burden of disease underscores the need for a granular understanding of the evolution of the disease and the factors associated with both disease progression and regression. Nonalcoholic fatty liver disease can progress to NASH, and NASH can both progress and regress without specific pharmacologic intervention.2,3,4,5,6 However, there is uncertainty around the rates of change and the associated factors, especially when accounting for baseline phenotype (ie, NAFL vs steatohepatitis, disease activity, and stage). Prior studies are mostly single-center, retrospective experiences and limited by small sample sizes, which do not capture the full spectrum of disease, and variable or unreported case definitions.7,8,9 This lack of data has hindered development of generalizable models of disease evolution that are needed both to guide patient care and to conduct clinical trials designed to evaluate the effect of therapy on progression to cirrhosis, which is the generally accepted surrogate end point for drug approval.10 Lack of data further limits development of robust population burden of disease models needed to inform policies regarding resource allocation to treat this disease. There is therefore an unmet need for data derived from prospective, multicenter, protocol-driven assessment of the histologic evolution of NAFLD using validated scoring systems implemented in a standardized manner. In this study, the histologic evolution of NAFLD and the factors associated with changes in disease severity over time were determined by analysis of prospectively collected clinical, laboratory, and histologic data from a cohort of participants with the full histologic spectrum of disease who underwent at least 2 liver biopsies more than 1 year apart. METHODS The NASH Clinical Research Network (CRN) is an ongoing National Institutes of Health–funded research network focused on better characterization of the clinical features and pathogenesis of NASH with the ultimate aim of developing improved means of its prevention and treatment. This analysis is a substudy of the NAFLD Database study (phases 1 and 2), a noninterventional registry of the network. The institutional review boards at each clinical center and the data coordinating center approved both protocols. All participants provided written informed consent. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline for cohort studies. Patient Populations Adults enrolled in the NAFLD Database study (phases 1 and 2) between October 27, 2004, and September 1, 2013, were included in this analysis if they had 2 evaluable biopsies 1 year or more apart. Histologic examination of liver biopsy specimens confirmed NAFLD in all cases. A daily consumption of alcohol less than 20 g for women and 30 g for men, as determined by the Alcohol Use Disorders Identification Test questionnaire,11 established the nonalcoholic nature of the liver disease. The baseline biopsy was either a historical biopsy performed prior to entry into the database or a liver biopsy performed within 90 days of enrollment. The patients received standard of care based on a networkwide standard-of-care document. Investigators performed follow-up biopsies based on clinical judgment. Individuals recruited into clinical trials from the NAFLD Database study and who were in the placebo arm of completed trials received a protocol-mandated biopsy and were included, while those in the active arm of such trials were excluded. Patients with nonevaluable biopsy samples (mean biopsy length, 5.2 mm) were excluded, as were those who underwent bariatric surgery or liver transplantation. Histologic Assessment Hematoxylin-eosin–stained slides as well as Masson trichrome–stained slides were coded and read in a masked manner by the pathology committee of the NASH CRN as described previously.12,13 The liver histologic characteristics were assessed and the individual features of NAFLD were identified and scored as previously described; the interrater concordance statistics for the assessment of NASH have also been previously published.12,14 We have recently reassessed these as part of an internal quality control process for the CRN pathology committee. The κ statistics for the specific findings were as follows: steatosis, 0.77 (95% CI, 0.69-0.84); ballooning, 0.54 (95% CI, 0.44-0.65); lobular inflammation, 0.46 (95% CI, 0.34-0.58); NAFLD activity score (NAS), 0.52 (95% CI, 0.44-0.6); fibrosis, 0.75 (95% CI, 0.67-0.82); and steatohepatitis diagnosis, 0.66 (95% CI, 0.57-0.75). Fatty liver (NAFL) was defined by steatosis with or without inflammation but without ballooning injury. This category also included some cases of steatosis with fibrosis without significant inflammation or ballooning in alignment with recent literature.15 Cases designated as borderline steatohepatitis had some but not all features of definite steatohepatitis, usually consisting of steatosis, inflammation, and appropriate fibrosis without ballooning. Definite steatohepatitis was defined by the presence of macrovesicular steatosis, inflammation, and hepatocellular ballooning in a mainly zone 3 distribution.16 Disease activity was determined from the severity of steatosis, lobular and portal inflammation, and characteristic hepatocellular ballooning. The NAS was computed by adding the severity scores for steatosis, lobular inflammation, and ballooning (range 0-8, with 8 indicating more severe disease).12 The minimum criteria for defining resolution of NASH was a disappearance of ballooning with modest or no residual inflammation.15 Resolution of NASH included those with resolution of NAFLD or residual NAFL. The definition of resolution of NAFLD included disappearance of hepatocellular ballooning with minimal or no lobular inflammation and a decrease in hepatic steatosis to less than 5% in the second biopsy. Clinical and Laboratory Data All clinical and laboratory data were collected prospectively after the patient consented to be screened for enrollment in the NASH CRN. Because some participants’ biopsies were historical, analyses of the associations between histologic and clinical and laboratory data were limited to a subset of participants with clinical and laboratory data collected within 6 months of the biopsy. Statistical Analysis Descriptive statistics were used to characterize individual groups of participants. Additional details are provided in the eMethods in the Supplement. Comparison of groups with or without steatohepatitis resolution or with fibrosis progression or regression was performed using t tests or analysis of variance for continuous measures, and Fisher exact test for categorical measures. Analysis of covariance adjusting for baseline values

Read the complete text